Prelude Therapeutics grants 275K stock options

Prelude Therapeutics granted its CLO, CFO and Corporate Secretary Bryant D. Lim an employee stock option covering 275,000 shares of common stock on February 4, 2026.

Rhea-AI Filing Summary

Prelude Therapeutics granted its CLO, CFO and Corporate Secretary Bryant D. Lim an employee stock option covering 275,000 shares of common stock on February 4, 2026. The option has an exercise price of $2.30 per share and is held as a direct ownership position.

The award vests over four years: 25% of the shares vest on February 4, 2027, and the remaining 75% vest in equal monthly installments of 1/48 of the total grant until fully vested, conditioned on Mr. Lim continuing to provide services to the company on each vesting date.

Insider Trade Summary

Grant/Award: 275,000 shares

Grant/Award 1 txn

Insider Lim Bryant David

Role CLO, CFO, Corp Sec.

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	275,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 275,000 contracts (Direct)

Footnotes (1)

1. F1. The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Prelude Therapeutics (PRLD) report for Bryant D. Lim?

Prelude Therapeutics reported that Bryant D. Lim received an employee stock option for 275,000 shares of common stock. The option was granted on February 4, 2026, and represents a direct ownership position as an equity-based compensation award.

What is the exercise price of the new Prelude Therapeutics (PRLD) stock option grant?

The employee stock option granted to Bryant D. Lim has an exercise price of $2.30 per share. This means he can buy Prelude Therapeutics common stock at $2.30 for the option’s duration, subject to the vesting schedule and continued service requirements.

How does the 275,000-share stock option for Prelude Therapeutics (PRLD) vest?

The 275,000-share stock option vests 25% on February 4, 2027, with the remaining shares vesting in equal monthly installments of 1/48 of the total grant. Vesting continues until fully vested, provided Bryant D. Lim remains in service on each vesting date.

Who is the reporting person in this Prelude Therapeutics (PRLD) Form 4 filing?

The reporting person is Bryant David Lim, who serves as Chief Legal Officer, Chief Financial Officer, and Corporate Secretary of Prelude Therapeutics. The Form 4 reports his receipt of an employee stock option incentive award from the company.

Is the Prelude Therapeutics (PRLD) stock option grant reported as direct or indirect ownership?

The Form 4 reports the 275,000-share employee stock option as held under direct ownership by Bryant D. Lim. No footnote indicates that the option is held through a separate entity or that beneficial ownership is disclaimed.

What type of security is disclosed in the Prelude Therapeutics (PRLD) insider filing?

The filing discloses an employee stock option, described as a right to buy Prelude Therapeutics common stock. The option covers 275,000 underlying shares and is structured as a time-vested equity compensation award subject to continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/05/2026 - 04:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lim Bryant David

(Last) (First) (Middle)

C/O PRELUDE THERAPEUTICS INCORPORATED

175 INNOVATION BOULEVARD

(Street)

WILMINGTON DE 19805

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Prelude Therapeutics Inc [ PRLD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CLO, CFO, Corp Sec.

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$2.3	02/04/2026		A		275,000		(1)	02/03/2036	Common Stock	275,000	$0.00	275,000	D

Explanation of Responses:

1. The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Remarks:

	/s/ Bryant D. Lim	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.